Showing results (161-170 of 976) with videos related to

Sort By:
Pageof 98
NPJ Breast Cancer|December 20, 2025
Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastasesKatarzyna J Jerzak, Evangelia D Razis, Elisa Agostinetto, et al.
NPJ Breast Cancer|December 9, 2025
HER2-low and ultralow expression of invasive breast carcinoma: clinicopathological features and immunohistochemical consistency analysisYu-Han Dong, Yi-Tong Xu, Xi-Zi Jiang, et al.
NPJ Breast Cancer|December 4, 2025
Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinionNeil M Iyengar, Joyce A O'Shaughnessy, Heather B Moore, et al.
NPJ Breast Cancer|February 15, 2025
A systematic review of determinants of breast cancer risk among women with benign breast diseaseAileen Burke, Jessica O'Driscoll, Mustapha Abubakar, et al.
NPJ Breast Cancer|December 18, 2024
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancerLinda Cucciniello, Eva Blondeaux, Claudia Bighin, et al.
NPJ Breast Cancer|February 10, 2025
Spatial proximity of CD8+ T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancerHongling Liang, Jianqing Huang, Hongsheng Li, et al.
NPJ Breast Cancer|February 8, 2025
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM studyRegina Peña-Enríquez, Begoña Bermejo, Marina Pollán, et al.
NPJ Breast Cancer|February 22, 2025
Sequence of therapy impact on older women with comorbidities and triple-negative or HER2-positive breast cancerNina Tamirisa, Wenli Dong, Yu Shen, et al.
NPJ Breast Cancer|January 8, 2025
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)Laura M Spring, Lauren Scarpetti, Arielle J Medford, et al.
NPJ Breast Cancer|December 6, 2024
Immunotherapy for hormone receptor‒positive HER2-negative breast cancerFatima Cardoso, Kim M Hirshfield, Kimberly A Kraynyak, et al.
Pageof 98